
GlaxoSmithKline’s (GSK) Pharmaceutical Tablet Manufacturing Factory, Karnataka
GlaxoSmithKline (GSK) began construction of an oral solid-dose manufacturing plant at the Vemgal Industrial Area in India in September 2015.
Merrion Pharmaceuticals is a publicly listed product development company focused on delivering innovation to the market by working on our own products and partnering to develop strategic products.
Merrion Pharmaceuticals is engaged in the development of oral forms (tablets / capsules) of drugs that have poor absorption and are generally given by injection.
We offer an uncomplicated, well validated and successful technology approach which is based on GRAS ingredients to develop a broad range of highly differentiated new products.
GIPET®’s unique approach allows drugs that currently can only be given parenterally (injectable) to be converted into oral (tablet / capsule) forms, as well as improving the absorption of current oral drugs.
GIPET uses specifically designed oral formulations of patented absorption enhancers which activate micelle formation, facilitating transport of the drug and substantially increasing absorption with good reproducibility and a strong safety profile.
In a database comprising more than 30 compounds having poor permeability, GIPET has shown the ability to improve their absorption by as much as 200 times, achieving excellent intersubject reproducibility with a positive safety database.
Merrion’s product development approach utilising GIPET offers the following benefits:
Orazol™ is a weekly oral tablet form of zoledronic acid, currently monthly infusion (Zometa®). Orazol is formulated in Merrion’s proprietary GIPET drug delivery technology.
Merrion has agreements with several pharmaceutical companies. In particular Merrion has partnered with Novo Nordisk, to develop oral insulin analogues and to develop and commercialise oral formulations of a Novo Nordisk proprietary GLP-1 receptor agonist, using Merrion’s proprietary (GIPET) technology.
Merrion has also partnered with Ferring Pharmaceuticals, a Swiss-based international pharmaceutical company, in the form of an oral drug delivery research collaborative programme with on an undisclosed compound. The aim of this study is to evaluate Merrion’s GIPET technology to boost the compound’s oral bioavailability.
From idea to final phase II formulation, oral drug delivery development can be carried out in our own cGMP facilities.
GlaxoSmithKline (GSK) began construction of an oral solid-dose manufacturing plant at the Vemgal Industrial Area in India in September 2015.
Eisai China has built a new oral solid dose (OSD) production facility at its new Suzhou plant in China.
Thank you for submitting the form. Your enquiry will be submitted to the company.
Thank you for subscribing to Pharmaceutical Technology